Learn about treatment emergent adverse events (TEAEs).
In clinical trials conducted with IYUZEH™ (latanoprost ophthalmic solution) 0.005% comparing it to XALATAN®, the most frequently reported ocular adverse reactions were conjunctival hyperemia (34% for IYUZEH vs 37% for XALATAN) and eye irritation (19% for IYUZEH vs 31% for XALATAN).1,2
IYUZEH (n=165) was well-tolerated with a lower incidence of overall ocular TEAEs compared to XALATAN (n=169) in the US phase III clinical trial.2,3,*
*TEAEs were calculated with a narrower definition of occurrence by investigators in this study compared to those reported in the PI, which contains ocular TEAEs reported by ≥1% of subjects receiving IYUZEH, accounting for the discrepancy in values calculated.
XALATAN is a registered trademark of Pfizer PFE Holdings 4 LLC, a Viatris Company.
Challenges of any preserved ophthalmic formulation include tolerability, worsening of ocular surface disease, and that can result in compliance issues. And so anything we can do to afford a patient the ability to stay on the drug is critical in the long-term strategic success in keeping people’s vision.
Visit our Video Library to Discover Why Eye Care Professionals are Choosing IYUZEH
Every time Ivan picks up his generic IOP-lowering medication, it is from a different generic manufacturer. Ivan is looking for a branded medication that gives him a consistent product and experience each refill.
†Patient portrayal. Not an actual patient.
IYUZEH™ (latanoprost ophthalmic solution) 0.005% is a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Known hypersensitivity to latanoprost or any other ingredients in this product.
IYUZEH may cause changes to pigmented tissues. Most frequently reported changes are increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as IYUZEH is administered. Iris pigmentation is likely to be permanent. Eyelid skin darkening and eyelash changes may be reversible.
IYUZEH may cause gradual change to eyelashes including increased length, thickness, and number of lashes. These changes are usually reversible upon discontinuation of treatment.
IYUZEH should be used with caution in patients with a history of intraocular inflammation (iritis/uveitis) and should generally not be used in patients with active intraocular inflammation.
IYUZEH should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
Reactivation of herpes simplex keratitis has been reported during treatment with latanoprost. IYUZEH should be used with caution in patients with a history of herpetic keratitis.
Contact lenses should be removed prior to the administration of IYUZEH and may be reinserted 15 minutes after administration.
The most common adverse reactions (5% to 35%) for IYUZEH are: conjunctival hyperemia, eye irritation, eye pruritus, abnormal sensation in eye, foreign body sensation in eyes, vision blurred, and lacrimation increased.
The combined use of two or more prostaglandins or prostaglandin analogs including IYUZEH is not recommended. It has been shown that administration of these prostaglandin drug products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP.
Please click here for the full Prescribing Information.
References: 1. IYUZEH™ (latanoprost ophthalmic solution) 0.005%. Prescribing information. Thea Pharma Inc; 2022. 2. Thea data on file. 2023. Clinical overview of T2345. 3. Bacharach J, Ahmed IIK, Sharpe ED, Korenfeld MS, Zhang S, Baudouin C. Preservative-free versus benzalkonium chloride–preserved latanoprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension: a phase 3 US clinical trial. Clin Ophthalmol. 2023;17:2575-2588.
